Guided Therapeutics Submits Positive LuViva Clinical Trial Results to FDA, Demonstrating Enhanced Detection of Precancerous Cervical Disease
Guided Therapeutics, Inc., a medical technology company focused on improving cervical cancer detection and prevention, has announced the submission of results from its multicenter clinical trial to the U.S. Food and Drug Administration (FDA). The study evaluated the performance of the company’s LuViva Advanced Cervical Scan, a noninvasive diagnostic platform designed to identify cervical disease using proprietary biophotonic technology.
The clinical trial findings suggest that LuViva may significantly improve the detection of precancerous cervical lesions that are often missed by current diagnostic approaches. According to the company, the results exceeded expectations and demonstrated the technology’s potential to address a longstanding challenge in cervical cancer screening and diagnosis.
The submission marks an important milestone for Guided Therapeutics as it seeks regulatory review of a technology that could enhance existing cervical cancer detection pathways and improve outcomes for women at risk of developing the disease.
Cervical Cancer Remains a Significant Global Health Concern
Despite major advances in screening and prevention, cervical cancer continues to be one of the most common cancers affecting women worldwide. Early detection of precancerous changes in cervical tissue remains critical because treatment at an early stage can prevent progression to invasive cancer.
For decades, screening programs have relied primarily on Pap tests and, more recently, human papillomavirus (HPV) testing to identify women who may be at increased risk of developing cervical cancer. Women with abnormal Pap smear results, positive HPV tests, or other concerning findings are typically referred for further evaluation through colposcopy and biopsy procedures.
While these diagnostic methods have played a vital role in reducing cervical cancer incidence, they are not without limitations. Studies have shown that some clinically significant precancerous lesions can be missed during routine colposcopy-directed biopsy procedures, potentially delaying diagnosis and treatment.
The challenge of identifying these missed lesions has created a need for technologies capable of improving diagnostic accuracy while remaining safe, efficient, and accessible for patients and healthcare providers.
Evaluating LuViva’s Clinical Performance
The multicenter clinical study conducted by Guided Therapeutics was specifically designed to evaluate whether the LuViva Advanced Cervical Scan could identify significant cervical disease that might otherwise go undetected using current standards of care.
The study protocol was developed through ongoing discussions and interactions with the FDA to ensure that the clinical design would appropriately address regulatory requirements and provide meaningful evidence regarding the device’s performance.
Researchers enrolled 480 women who had been referred for cervical biopsy following abnormal Pap test results, positive HPV findings, or both. These patients represented a population already considered at elevated risk for cervical disease and therefore suitable for further diagnostic evaluation.
Of the 480 women enrolled in the study, 428 completed all required procedures and assessments. Independent expert pathologists reviewed biopsy specimens and determined that 99 participants had clinically significant cervical disease that could potentially progress to cervical cancer if left untreated.
This patient population provided investigators with an opportunity to assess how effectively LuViva could identify disease in comparison with existing diagnostic approaches.
Identifying Disease Missed by Standard Diagnostic Methods
One of the most notable findings from the study involved lesions that were not detected through conventional colposcopy-directed biopsy procedures.
Among the 99 women confirmed to have significant cervical disease, investigators found that 32 cases—representing approximately 32.3% of all disease-positive participants—were missed by the current standard of care.
These findings highlight a well-recognized limitation within cervical disease diagnostics. Although colposcopy-directed biopsies remain an important diagnostic tool, they can fail to identify certain lesions due to sampling limitations, visualization challenges, or other procedural factors.
The primary objective of the trial was to determine whether LuViva could successfully detect a meaningful proportion of these missed disease cases.
According to the study results, the device achieved this objective and exceeded expectations.
Significant Improvement in Detection Rates
The trial demonstrated that LuViva identified 21 of the 32 significant disease cases that were missed by standard colposcopy-directed biopsy procedures.
This translated to a detection rate of approximately 66% for lesions that would otherwise have gone undiagnosed using conventional methods alone.
When LuViva was incorporated into the diagnostic process, overall disease detection increased substantially.
The study showed that detection rates improved from 68% under the existing standard of care to 89% when LuViva findings were included.
Such an improvement could have meaningful clinical implications. Detecting precancerous lesions earlier provides healthcare providers with opportunities to intervene before disease progresses to invasive cervical cancer. Earlier treatment can improve patient outcomes while potentially reducing healthcare costs associated with advanced disease management.
The ability to identify lesions that are frequently overlooked by conventional procedures could make LuViva a valuable complement to current cervical screening and diagnostic strategies.
Strong Statistical Performance Across Study Endpoints
In addition to demonstrating improved disease detection, the study also met all primary and secondary performance endpoints established for the trial.
Researchers reported that LuViva achieved the required measures for both sensitivity and specificity, two key metrics used to evaluate diagnostic technologies.
Sensitivity reflects a test’s ability to correctly identify patients who have disease, while specificity measures the ability to accurately identify those who do not have disease. Achieving strong performance in both categories is essential for any diagnostic tool intended for widespread clinical use.
According to Guided Therapeutics, all endpoints were met with a high degree of statistical confidence. The reported statistical significance level of p < 0.0001 indicates an extremely low probability that the observed results occurred by chance.
Such findings provide strong support for the reliability and robustness of the study outcomes.
Favorable Safety Profile Observed
Safety was another important component of the clinical evaluation.
Throughout the study, investigators monitored participants for any adverse events or safety concerns associated with the use of the LuViva device.
The company reported that no safety issues or device-related adverse events occurred among study participants.
This favorable safety profile is particularly noteworthy because LuViva is designed as a rapid, painless, and noninvasive procedure. Unlike biopsy-based diagnostic methods that require tissue sampling, the technology uses proprietary biophotonic scanning techniques to assess cervical tissue without causing discomfort or requiring invasive intervention.
The absence of reported safety concerns further supports the potential utility of the technology in routine clinical settings.
Biophotonic Technology Offers a Novel Approach
LuViva utilizes patented biophotonic technology to evaluate cervical tissue characteristics in real time.
Rather than relying solely on visual inspection or tissue removal, the system analyzes how light interacts with cervical tissue. These optical signatures can provide information about underlying cellular and structural changes associated with precancerous disease.
The technology is designed to deliver rapid results while minimizing patient discomfort and reducing procedural complexity.
As healthcare systems increasingly seek tools that improve diagnostic accuracy while enhancing the patient experience, noninvasive technologies such as LuViva may become increasingly attractive options for clinicians.
Company Leadership Highlights Clinical Significance
Guided Therapeutics President and Chief Executive Officer Mark Faupel described the study results as exceeding company expectations and emphasized the potential clinical impact of the findings.
According to Faupel, the ability of LuViva to identify significant precancerous lesions that are missed by conventional diagnostic methods addresses an important unmet need in women’s healthcare.
He noted that the company is looking forward to working with the FDA during the regulatory review process and plans to collaborate with physician investigators to publish the study findings in a leading peer-reviewed medical journal.
Publication of the results could further validate the technology within the medical community and provide clinicians with additional data regarding its potential role in cervical cancer prevention.
The FDA submission represents a critical next step in Guided Therapeutics’ efforts to bring LuViva into broader clinical use. If regulatory review confirms the technology’s effectiveness and safety, LuViva could become an important addition to existing cervical cancer screening and diagnostic pathways.
By helping physicians identify precancerous lesions that may otherwise remain undetected, the technology has the potential to improve early diagnosis, support timely treatment, and ultimately contribute to reducing the burden of cervical cancer.
As healthcare providers continue searching for more accurate and patient-friendly diagnostic solutions, the positive clinical trial results position LuViva as a promising innovation in the ongoing fight against cervical cancer and its precancerous precursors.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports.
